info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Gabapentin Companies

Gabapentin is a medication commonly prescribed for the treatment of various conditions, including epilepsy, neuropathic pain, and restless legs syndrome. Different pharmaceutical companies may manufacture and distribute gabapentin under various brand names.

Gabapentin Key CompaniesLatest Gabapentin Companies Update



  • March 2023: Granules India Ltd., a pharmaceutical company, obtained authorization from the United States health regulator to market its generic gabapentin tablets, which are designed to treat postherpetic neuralgia in adults. Granules India stated in a regulatory filing that the US Food and Drug Administration (FDA) has granted approval for the abbreviated new drug application (ANDA) for Gabapentin tablets with concentrations of 600 mg and 800 mg. These tablets are bioequivalent to the reference listed drug product of Viatris Specialty LLC, Neurontin Tablets, 600 mg and 800 mg. The company added that gabapentin tablets are approved for the treatment of postherpetic neuralgia in adults and partial onset seizures, with or without secondary generalization, in adults and pediatric patients with epilepsy aged 3 years and older as an adjunctive therapy.




  • January 2023: The United States Food and Drug Administration (FDA) granted final approval to Glenmark Pharmaceuticals Limited (Glenmark), a research-driven multinational pharmaceutical company, for Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg. Tadalafil is the generic equivalent of Cialis®1 Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg, manufactured by Eli Lilly and Company. Based on sales data from IQVIAâ„¢ for the twelve-month period concluding in November 2020, the market for Cialis® Tablets in the following strengths (2.5 mg, 5 mg, 10 mg, and 20 mg) generated an estimated annual revenue of $125.5 million*. Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg, the generic equivalent of Horizant®1 Extended-Release Tablets, 300 mg and 600 mg, manufactured by Arbor Pharmaceuticals, LLC, have also been provisionally approved by the U.S. FDA for Glenmark.


List of Gabapentin Key companies in the market

  • Zydus Pharmaceuticals, Inc

  • Glenmark Pharmaceuticals Limited

  • Sun Pharmaceutical Industries Ltd.

  • Ascend Laboratories, LLC

  • Apotex Inc.

  • Teva Pharmaceutical Industries Ltd.

  • Aurobindo Pharma.

  • Amneal Pharmaceuticals LLC.

  • Cipla USA, Inc.

  • BP Pharmaceuticals Laboratories Company

  • Assertio Holdings, Inc.

  • Arbor Pharmaceuticals, Inc.

  • Pfizer Inc.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.